Treatment
[177Lu]Lu-PSMA I&T clinical trials
We’re tracking 6 recruiting studies that include [177Lu]Lu-PSMA I&T, each written for real people, not researchers, below.
Recruiting studies
- NCT06866938RecruitingPhase 2
Second course of PSMA-targeted radiation for prostate cancer
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
BordeauxAges 18 years+ - NCT06828263Recruiting
Imaging markers during PSMA therapy for prostate cancer
This trial is testing a new imaging approach during treatment with a radioactive drug (Lu-PSMA) for men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if imaging changes can help predict how well the treatment is working.
GrenobleAges 18 years+ - NCT05893381RecruitingPhase 2
Targeted PSMA scan plus focused radiation vs radiation alone
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
Cesena, FCAges 18 years+ - NCT06220188RecruitingPhase 2
PSMA therapy for prostate cancer that has come back
This trial tests a targeted radiation therapy (PSMA-RLT) for men whose prostate cancer has returned after initial treatment, shown only by rising PSA levels. It aims to control the cancer without using hormone therapy.
ViennaAges 18–80 - NCT06259123RecruitingPhase 2
PSMA Radiotherapy Before Prostate Cancer Surgery
This trial tests a radioactive drug (PSMA-RLT) given before surgery for prostate cancer that has spread to a few spots. It aims to see if this treatment can stop the cancer from growing further.
ViennaAges 18–75 - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new drug to standard care for prostate cancer
This trial tests a new study drug (AAA817) against the usual treatments for men with a certain type of advanced prostate cancer that has spread and is no longer responding to a targeted radiation therapy (177Lu-PSMA). The goal is to see if the new drug can help control the disease longer.
Los Angeles, CaliforniaAges 18–100
What [177Lu]Lu-PSMA I&T is being studied for
Conditions with recruiting [177Lu]Lu-PSMA I&T studies.
Common questions
- Are there clinical trials studying [177Lu]Lu-PSMA I&T?
- Yes. Clin2 currently lists 6 recruiting studies that include [177Lu]Lu-PSMA I&T, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a [177Lu]Lu-PSMA I&T trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is [177Lu]Lu-PSMA I&T an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether [177Lu]Lu-PSMA I&T or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.